Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
By
Wayne Kuznar
Pediatric Cancer
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected.
Read Article
Patient Navigators, Clinician Education Can Remove Barriers to Enrollment in Clinical Trials
By
Chase Doyle
Patient Navigation
,
Value-Based Care
,
Personalized Medicine
,
Economics & Value
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Fewer than 7% of adults with cancer and even fewer minority patients participate in clinical trials, which negatively affects the ability to determine the safety and efficacy of new and investigational therapies. At ASCO 2019, 2 experts discussed strategies to overcome the barriers to clinical trial participation and to help enroll more patients with cancer in them.
Read Article
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
In the Literature
,
Lymphoma
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
The 2 chimeric antigen receptor (CAR) T-cell therapies available so far—axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah)—may be considered cost-effective treatments for adults with diffuse large B-cell lymphoma (DLBCL), depending on the long-term outcomes of these patients, according to a recent cost-effective analysis (Lin JK, et al.
J Clin Oncol.
2019 Jun 3. Epub ahead of print).
Read Article
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Hematologic Malignancies
,
In the Literature
,
Multiple Myeloma
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Until recently, patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation (ASCT), the multiagent regimen with lenalidomide (Revlimid) and dexamethasone was the standard of care. Results of the prespecified interim analysis of the MAIA trial demonstrated the benefit of adding daratumumab (Darzalex) to this combination therapy (Facon T, et al.
N Engl J Med.
2019;380:2104-2115).
Read Article
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—BLU-667, a novel inhibitor of RET, elicited responses in more than 50% of patients with
RET
fusion–positive advanced non–small-cell lung cancer (NSCLC), according to data from an ongoing phase 1 clinical trial presented at ASCO 2019.
Read Article
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with
ROS1
rearrangement, induced a response in 9 of 11 patients with TKI-naïve, advanced non–small-cell lung cancer (NSCLC) and
ROS1
fusion.
Read Article
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—With 475 cell and gene therapy companies in North America representing a business enterprise with approximately $20 billion, new immunotherapies are moving rapidly from the laboratory to the clinic. As chimeric antigen receptor (CAR) T-cell therapy makes its way from the academic to community setting, however, appropriate resources and infrastructure are required to ensure the safe and effective management of patients.
Read Article
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers. But translating this success to solid tumors remains a challenge. At ASCO 2019, Gianpietro Dotti, MD, Cancer Cellular Immunotherapy Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, discussed efforts to extend the application of CAR T-cell therapy to solid tumors
Read Article
How CAR T-Cell Therapy Gave Cherie Rineker Her Life Back
Immunotherapy
,
Multiple Myeloma
,
Hematologic Malignancies
,
Personalized Medicine
Web Exclusives
Read Article
Osimertinib plus Savolitinib Promising for Advanced Non–Small-Cell Lung Cancer and MET-Driven Resistance
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
June 2019, Vol 10, No 3
Atlanta, GA—The combination of the investigational MET inhibitor savolitinib plus the EGFR inhibitor osimertinib (Tagrisso) achieved encouraging responses in patients with
MET
-amplified,
EGFR
-positive non–small-cell lung cancer (NSCLC) and acquired,
MET
-driven resistance to previous therapies, with an acceptable side-effect profile. These findings represent interim results of 2 expansion cohorts of a phase 1b clinical trial presented at the 2019 American Association for Cancer Research meeting.
Read Article
Page 4 of 35
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma